Kengo Nagashima



About

I am a Project Associate Professor at The Institute of Statistical Mathematics.

My (current) primary research interests are (1) Survival Analysis and Model Selection, (2) Meta-analysis and Inference for Random-effects Models, and (3) Model Misspecification.

Curriculum vitae (PDF)

Logo: The Institute of Statistical Mathematics

Contact Informations

The Institute of Statistical Mathematics
10-3 Midori-cho, Tachikawa, Tokyo 190-8562, Japan.
E-mail:
Website: https://nshi.jp/en/

Education

Professional Positions

Paper(s) Under Review

  1. Hamaguchi Y, Noma H, Nagashima K, Yamada T, Furukawa TA. Frequentist performances of Bayesian prediction intervals for random-effects meta-analysis. Under review. [arXiv:1907.00345]
  2. Nagashima K, Noma H, Furukawa TA. pimeta: an R package of prediction intervals for random-effects meta-analysis. Under review.
  3. Nagashima K, Noma H, Sato Y, Gosho M. Sample size calculations for the Kaplan–Meier estimator in single-arm survival studies. Under review.

Selected Publications (Peer-Reviewed)

    Statistical Methodology / Applications and Reviews in Biostatistics

  1. Noma H, Nagashima K, Furukawa TA. Permutation inference methods for multivariate meta-analysis. Biometrics 2019. In press. DOI: 10.1111/biom.13134. [arXiv:1809.03935]
  2. Nagashima K, Noma H, Furukawa TA. Prediction intervals for random-effects meta-analysis: a confidence distribution approach. Statistical Methods in Medical Research 2019;28(6):1689–1702. DOI: 10.1177/0962280218773520. [arXiv:1804.01054] [Software]
  3. Noma H, Nagashima K, Maruo K, Gosho M, Furukawa TA. Bartlett-type corrections and bootstrap adjustments of likelihood-based inference methods for network meta-analysis. Statistics in Medicine 2018;37(7):1178–1190. DOI: 10.1002/sim.7578.
  4. Sato Y, Gosho M, Nagashima K, Takahashi S, Ware JH, Laird NM. Statistical methods in the Journal — an update. New England Journal of Medicine 2017;376(11):1086–1087. DOI: 10.1056/NEJMc1616211. (Correspondence)
  5. Nagashima K, Sato Y. Information criteria for Firth's penalized partial likelihood approach in Cox regression models. Statistics in Medicine 2017;36(21):3422–3436. DOI: 10.1002/sim.7368. [Postprint]
  6. Noma H, Nagashima K. A note on the Mantel–Haenszel estimators when the common effect assumptions are violated. Epidemiologic Methods 2016;5(1):19–35. DOI: 10.1515/em-2015-0004.
  7. Nagashima K, Sato Y, Noma H, Hamada C. An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach. Statistics in Medicine 2013;32(27):4838–4858. DOI: 10.1002/sim.5895. [arXiv:1805.05017]
  8. Nagashima K, Sato Y, Hamada C. A modified maximum contrast method for unequal sample sizes in pharmacogenomic studies. Statistical Applications in Genetics and Molecular Biology 2011;10(1):Article 41. DOI: 10.2202/1544-6115.1560. [Postprint] [Software]
  9. Medical Researches

  10. Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, On behalf of the PRIME-V study group. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomised controlled study (PRIME-V study). Diabetes, Obesity and Metabolism 2019. In press. DOI: 10.1111/dom.13750.
  11. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K-i, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, for the Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Safety and efficacy of eculizumab in Guillain–Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet Neurology 2018;17(6):519–529. DOI: 10.1016/S1474-4422(18)30114-5.
  12. Watanabe K, Hirano S, Kojima K, Nagashima K, Mukai H, Sato T, Takemoto M, Matsumoto K, Iimori T, Isose S, Omori S, Shibuya K, Sekiguchi Y, Beppu M, Amino H, Suichi T, Yokote K, Uno T, Kuwabara S, Misawa S. Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. Journal of Neurology, Neurosurgery, and Psychiatry 2018;89(10):1082–1087. DOI: 10.1136/jnnp-2017-316601.
  13. Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y, Takashima A, Kato K, Hamaguchi T. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. Gastric Cancer 2018;21(3):439–445. DOI: 10.1007/s10120-017-0753-2.
  14. Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. International Journal of Clinical Oncology 2018;23(2):382–388. DOI: 10.1007/s10147-017-1200-4.
  15. Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Hamaguchi T. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget 2017;8(56):95083–95094. DOI: 10.18632/oncotarget.18297.
  16. Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Boku N. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer 2017;20(4):655–662. DOI: 10.1007/s10120-016-0670-9.
  17. Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Akagi R, Yamaguchi T, Takahashi K, Nagashima K, Takahashi K. Quantitative US elastography can quantify mechanical and histological tendon healing in a rabbit model of achilles tendon transection. Radiology 2017;283(2):408–417. DOI: 10.1148/radiol.2016160695.
  18. Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I, Ikeda S-i, Kohara N, Kanda T, Kira J-i, Hanaoka H, Kuwabara S, for the Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2016;15(11):1129–1137. DOI: 10.1016/S1474-4422(16)30157-0.
  19. Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunology Research 2016;4(7):592–599. DOI: 10.1158/2326-6066.CIR-15-0298.

Funding History

    Biostatistics

  1. Statistical inference for random-effects meta-analyses under model misspecification. Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant-in-Aid for Young Scientists. April 2019–March 2022. Grant number: 19K20229. (PI)
  2. Statistical inference, prediction, and modeling for network meta-analysis. Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant-in-Aid for Scientific Research (B). April 2019–March 2022. Grant number: 19H04074. (Co-I)
  3. Statistical inference for rare event data and its application in clinical researches. Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant-in-Aid for Young Scientists (B). April 2016–March 2019. Grant number: 16K16014. (PI)
  4. Medical Researches

  5. Health literacy improvement of cervical cancer prevention using information and communications technology. Japan Society for the Promotion of Science (JSPS) KAKENHI, Challenging Research (Exploratory). July 2019–March 2022. Grant number: 19K22737. (Co-I)
  6. Development of an efficient screening method for the early detection and risk stratification of pancreatic cancer. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. December 2018–March 2020. (Co-I)
  7. Practical research of blood biomarkers for predicting effects of postoperative adjuvant chemotherapies by metastatic activity analysis of non-small cell lung cancer. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. April 2017–March 2020. (Co-I)
  8. Developing an early-detection and risk-stratification biomarkers for cancer by analyzing post-translational modifications to proteins and peptides. Japan Agency for Medical Research and Development, Project for Cancer Research and Therapeutic Evolution (P-CREATE). April 2017–March 2022. (Co-I)
  9. Evaluation study for efficacy and safety of drug therapy based on sex differences. Japan Agency for Medical Research and Development, Project for Whole Implementation to Support and Ensure the female life—Wise. November 2016–March 2019. (Co-I)
  10. Development of efficient screening method for early detection and risk stratification of pancreatic cancer. Japan Agency for Medical Research and Development, Practical Research for Innovative Cancer Control. September 2016–March 2017. (Co-I)

Teaching History

Professional Activities

Journal Reviewer

Softwares

Last updated date